These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17174215)

  • 1. [Use of heparin and platelet GPIIbIIIa inhibitor tirofiban for cardiac surgery in patients for suspicion of heparin-induced thrombocytopenia].
    Commin PL; Rozec B; Trossaërt M; Le Teurnier Y; Fournet X; Blanloeil Y
    Ann Fr Anesth Reanim; 2006; 25(11-12):1153-7. PubMed ID: 17174215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant.
    Koster A; Loebe M; Mertzlufft F; Kuppe H; Hetzer R
    Ann Thorac Surg; 2000 Dec; 70(6):2160-1. PubMed ID: 11156147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade.
    Durand M; Lecompte T; Hacquard M; Carteaux JP
    Eur J Cardiothorac Surg; 2008 Sep; 34(3):687-9. PubMed ID: 18579401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
    Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
    Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.
    Koster A; Meyer O; Fischer T; Kukucka M; Krabatsch T; Bauer M; Kuppe H; Hetzer R
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1254-5. PubMed ID: 11726910
    [No Abstract]   [Full Text] [Related]  

  • 6. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
    Bizzarri F; Scolletta S; Tucci E; Lucidi M; Davoli G; Toscano T; Neri E; Muzzi L; Frati G
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1181-5. PubMed ID: 11726894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.
    Mulot A; Moulin F; Fohlen-Walter A; Angioi M; Sghaier M; Carteaux JP; Lecompte T; de Maistre E
    Am J Hematol; 2004 Sep; 77(1):67-71. PubMed ID: 15307109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two consecutive open heart operations in a small child with heparin-induced thrombocytopenia type II using anticoagulation with heparin and tirofiban.
    Neuray M; Balling G; Schreiber C; Martin K
    Ann Thorac Surg; 2012 Aug; 94(2):653-5. PubMed ID: 22579887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons.
    Hiramatsu Y; Gikakis N; Anderson HL; Gorman JH; Marcinkiewicz C; Gould RJ; Niewiarowski S; Edmunds LH
    J Thorac Cardiovasc Surg; 1997 Jan; 113(1):182-93. PubMed ID: 9011688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting.
    Beiras-Fernandez A; Kowert A; Jiru P; Weis M; Spannagl M; Reichart B; Schmoeckel M
    Ann Thorac Surg; 2009 Feb; 87(2):629-31. PubMed ID: 19161801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies.
    Schreiber C; Dietrich W; Braun S; Kostolny M; Eicken A; Lange R
    Clin Res Cardiol; 2006 Jul; 95(7):379-82. PubMed ID: 16779503
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
    N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Pinto DS; Sperling RT; Tu TM; Cohen DJ; Carrozza JP
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):65-8. PubMed ID: 12508198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor].
    Christen JR; Soubrier C; Martinez E; Roumieu V; Darmon O; Scandaliaris S; Picou L; Cuisset T; Grados A; Bernit E; Ebbo M; Harlé JR; Schleinitz N
    Rev Med Interne; 2017 Nov; 38(11):769-773. PubMed ID: 28690092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases.
    Abdeladim S; Elharras M; Elouarradi A; Bensahi I; Oualim S; Merzouk F; Sabry M
    Pan Afr Med J; 2021; 38():9. PubMed ID: 33520078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial.
    Adamo M; Ariotti S; Costa F; Curello S; Moschovitis A; de Vries T; White HD; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1667-76. PubMed ID: 27539685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.